SCHEMBL15919281

SCHEMBL15919281

CC(C)(C)OC(=O)NNC(=O)c1cc(-c2ccc(C#Cc3ccc(NS(C)(=O)=O)cc3)cc2)nc2ccncc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 4/20 0.41
▸ ACACA Q13085 3/20 0.41
▸ MAPK10 P53779 1/20 0.39
▸ MAPT P10636 5/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ MEN1 O00255 5/20 0.38
▸ KMT2A Q03164 5/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ HSP90AA1 P07900 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CYP3A4 P08684 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ GAA P10253 2/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15919518 0.88 KMT2A (0.46) ACACBACACAMAPTKDM4ENPSR1
SCHEMBL15919517 0.85 ACACB (0.44) ACACBACACAMAPTKDM4ENPSR1
SCHEMBL15904908 0.84 ACACB (0.46) ACACBACACAMAPTKDM4ENPSR1
SCHEMBL15905544 0.84 MAPK10 (0.44) MAPK10MAPTKDM4ENPSR1HTT
Hydrochloric Acid SCHEMBL15905183 0.84 MAPK10 (0.43) MAPK10MAPTKDM4ENPSR1HTT
SCHEMBL15905078 0.82 MEN1 (0.51) ACACBACACAMAPTKDM4ENPSR1
SCHEMBL15919508 0.81 ACACB (0.48) ACACBACACAMAPTKDM4ENPSR1
SCHEMBL15919431 0.80 ACACB (0.44) ACACBACACAMAPTKDM4ENPSR1
SCHEMBL15919479 0.80 RAB9A (0.41) ACACBACACAMAPTKDM4ENPC1
SCHEMBL15919445 0.80 MAPT (0.48) ACACBACACAMAPTKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 — — US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 — — US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 — — US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 — — US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO ACACB 1141/4885ACACA 1262/4885MAPK10 3106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback